Our analysis suggested that at least 57% of MABC clinical isolates were susceptible to macrolides owing to the loss of function of erm(41), suggesting that macrolide-containing regimens are effective in treating more than half of MABC infections in our cohort. This evidence concerns the gene ETV5 and infection.